Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: A Review of Links and Risks
Amanda Cheung, Aijaz Ahmed
Clinical and Experimental Gastroenterology (2021) Vol. Volume 14, pp. 457-465
Open Access | Times Cited: 21

Showing 21 citing articles:

Steatotic liver disease, MASLD and risk of chronic kidney disease
Josh Bilson, Alessandro Mantovani, Christopher D. Byrne, et al.
Diabetes & Metabolism (2023) Vol. 50, Iss. 1, pp. 101506-101506
Open Access | Times Cited: 33
Metabolic dysfunction–associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease
Marenao Tanaka, Kazuma Mori, Satoko Takahashi, et al.
Nephrology Dialysis Transplantation (2022) Vol. 38, Iss. 3, pp. 700-711
Closed Access | Times Cited: 36
Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Clinical and Research Implications
Amedeo Lonardo, Alessandro Mantovani, Giovanni Targher, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 21, pp. 13320-13320
Open Access | Times Cited: 36
MAFLD and CKD: An Updated Narrative Review
Alessandro Mantovani, Rosa Lombardi, Filippo Cattazzo, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 13, pp. 7007-7007
Open Access | Times Cited: 34
MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials
Faı̈ez Zannad, Arun J. Sanyal, Javed Butler, et al.
Journal of Internal Medicine (2024) Vol. 296, Iss. 1, pp. 24-38
Open Access | Times Cited: 6
Metabolic Syndrome but Not Fatty Liver-Associated Genetic Variants Correlates with Glomerular Renal Function Decline in Patients with Non-Alcoholic Fatty Liver Disease
Francesco Baratta, Laura D’Erasmo, Alessia Di Costanzo, et al.
Biomedicines (2022) Vol. 10, Iss. 3, pp. 720-720
Open Access | Times Cited: 10
Lower prevalence of elevated liver stiffness measurements in people with type 2 diabetes taking sodium-glucose co-transporter 2 inhibitors or glucagon-like peptide-1 receptor agonists
Lucy Gracen, Withma Muthukumara, Melanie Aikebuse, et al.
Annals of Hepatology (2023) Vol. 28, Iss. 6, pp. 101142-101142
Open Access | Times Cited: 5
The Pivotal Role of the Membrane-Bound O-Acyltransferase Domain Containing 7 in Non-Alcoholic Fatty Liver Disease
Preethi Chandrasekaran, Ralf Weiskirchen
Livers (2023) Vol. 4, Iss. 1, pp. 1-14
Open Access | Times Cited: 4
Use of Machine Learning to Predict Onset of NAFLD in an All-Comers Cohort—Development and Validation in 2 Large Asian Cohorts
Daniel Yan Zheng Lim, Goh Eun Chung, Pei Hua Cher, et al.
Gastro Hep Advances (2024) Vol. 3, Iss. 7, pp. 1005-1011
Open Access | Times Cited: 1
Impact of non‐alcoholic fatty liver disease and fibrosis on mortality and kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A multi‐cohort longitudinal study
Lijun Zhao, Qingyue Zeng, Xiaoqin Zhou, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 10, pp. 4241-4250
Closed Access | Times Cited: 1
Glucagon and glucagon‐like peptide‐1 dual agonist therapy: A possible future towards fatty kidney disease
Mehmet Kanbay, Mazlum Çöpür, Mustafa Güldan, et al.
European Journal of Clinical Investigation (2024)
Open Access | Times Cited: 1
Risk Prevention and Health Promotion for Non-Alcoholic Fatty Liver Diseases (NAFLD)
Adnan Khan, Heather M. Ross, Natalia Salinas Parra, et al.
Livers (2022) Vol. 2, Iss. 4, pp. 264-282
Open Access | Times Cited: 7
Clinical Trajectory and Predictors of Intensive Care Unit Mortality Among Nonalcoholic Fatty Liver Disease Patients: A Retrospective Case–Control Study
Eiad Janini, Bashar Fteiha, Imran Ramlawi, et al.
Journal of Clinical and Experimental Hepatology (2022) Vol. 13, Iss. 2, pp. 218-224
Open Access | Times Cited: 3
Collagen-Targeted Protein Nanomicelles for the in vivo Imaging of Non-Alcoholic Steatohepatitis (NASH)
Andrew Wang, Orin Mishkit, Heather Mao, et al.
(2024)
Closed Access
Collagen-targeted Protein Nanomicelles for the Imaging of Non-Alcoholic Steatohepatitis
Andrew L. Wang, Orin Mishkit, Heather Mao, et al.
Acta Biomaterialia (2024) Vol. 187, pp. 291-303
Closed Access
Defining Renal Recovery in Patients With Hepatorenal Syndrome‐Acute Kidney Injury: Experience From North American Studies
Muhammad A. Mujtaba, Hussien Elsiesy, Sara Faiz, et al.
JGH Open (2024) Vol. 8, Iss. 12
Open Access
Association of circulating inflammatory proteins with Nonalcoholic Fatty Liver Diseas: a bidirectional Mendelian randomization study
Ming-Jie Jia, Long Chen, Hui-Lin Li
Research Square (Research Square) (2024)
Open Access
Digestive system diseases and a chronic kidney disease — the two sides of the healthcare global problems
А. М. Осадчук, I. D. Loranskaya, М. А. Осадчук
Russian Journal of Preventive Medicine (2024) Vol. 27, Iss. 7, pp. 108-108
Closed Access
Liver stiffness, hepatorenal index, and microRNA-130b as predictors for chronic kidney disease in patients with non-alcoholic fatty liver disease
Mohamed Yosef El Hassafy, Abeer Elhadidi, Mona Mostafa Tahoon, et al.
Egyptian Liver Journal (2023) Vol. 13, Iss. 1
Open Access
Vascular endothelial cell-specific overexpression of CNP did not improve liver fibrosis in HFFCD-induced NASH, but did improve renal lesions
Takuya Ensho, Jun Hino, Yôko Ueda, et al.
Peptides (2023) Vol. 172, pp. 171146-171146
Closed Access
The Entanglement between Metabolic Associated Non- Alcoholic Fatty liver Disease and Chronic Kidney Disease Progression is more than just a Strong Correlation. A Narrative Review
Mohamed Ahmed Nasreldin
International Journal of Clinical Nephrology (2022) Vol. 4, Iss. 2, pp. 01-12
Open Access
Page 1

Scroll to top